ThinkEquity Downgrades Navidea Biopharmaceuticals (NAVB) to Hold
Tweet
Share
E-mailGet Alerts NAVB Hot Sheet
Price: $0.00 --0%
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
ThinkEquity downgraded Navidea Biopharmaceuticals (NYSE: NAVB) from Buy to Hold with a price target of $2.50 after the FDA failed to approve Lymphoseek.
For an analyst ratings summary and ratings history on Navidea Biopharmaceuticals click here. For more ratings news on Navidea Biopharmaceuticals click here.
Shares of Navidea Biopharmaceuticals closed at $3.51 yesterday.
For an analyst ratings summary and ratings history on Navidea Biopharmaceuticals click here. For more ratings news on Navidea Biopharmaceuticals click here.
Shares of Navidea Biopharmaceuticals closed at $3.51 yesterday.
Create E-mail Alert Related Categories
DowngradesRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
